Traders Buy High Volume of Put Options on Veru (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERU) saw some unusual options trading activity on Tuesday. Stock traders purchased 4,729 put options on the stock. This is an increase of 95% compared to the typical volume of 2,430 put options.

Institutional Investors Weigh In On Veru

Several large investors have recently added to or reduced their stakes in the stock. Weaver Consulting Group lifted its position in shares of Veru by 27.4% in the 1st quarter. Weaver Consulting Group now owns 88,838 shares of the company’s stock worth $44,000 after purchasing an additional 19,133 shares during the period. Wells Fargo & Company MN lifted its position in shares of Veru by 37.1% in the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock worth $49,000 after purchasing an additional 20,430 shares during the period. Integrated Wealth Concepts LLC lifted its position in shares of Veru by 31.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company’s stock worth $56,000 after purchasing an additional 20,500 shares during the period. Gladstone Institutional Advisory LLC lifted its position in shares of Veru by 52.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company’s stock worth $57,000 after purchasing an additional 30,000 shares during the period. Finally, Cetera Investment Advisers lifted its position in shares of Veru by 26.1% in the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company’s stock worth $62,000 after purchasing an additional 19,724 shares during the period. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Stock Performance

Veru stock traded down $0.02 during trading hours on Tuesday, hitting $0.58. The company had a trading volume of 586,447 shares, compared to its average volume of 1,898,574. The firm has a market cap of $84.58 million, a P/E ratio of -2.24 and a beta of -0.80. Veru has a 1 year low of $0.45 and a 1 year high of $1.42. The company has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.61.

Veru (NASDAQ:VERU) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. As a group, equities research analysts anticipate that Veru will post -0.22 EPS for the current year.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.